英文药名：ZACRAS Combination Tablets LD/HD（Azilsartan/Amlodipine Besilate）

中文药名：阿齐沙坦/氨氯地平结合片

日文药名：ザクラス配合錠LD／ザクラス配合錠HD

生产厂家：武田药品
药品介绍
药品名称：阿齐沙坦氨氯地平片
英文名称：Azilsartan/Amlodipine Besilate Combination Tablets LD/HD
商品名：Zacras
适应症：高血压症
剂量和给药方法
成人每日一次，每次一片
剂型及规格包装
配合錠LD（20mg/2.5mg）
100錠（10錠×10）、140錠（14錠×10）、500錠（バラ、10錠×50）、700錠（14錠×50）
配合錠HD（20mg/5mg）
100錠（10錠×10）、140錠（14錠×10）、500錠（バラ、10錠×50）、700錠（14錠×50）

生产厂商
日本武田药品有限公司
产品特点：
阿齐沙坦（zilsartan）是一种血管紧张素II受体阻滞剂（ARB），通过阻断血管升压激素血管紧张素II发挥降血压作用；氨氯地平（amlodipine）是一种钙通道阻滞剂（CCB），通过抑制血管平滑肌细胞内向钙通道发挥降血压作用，导致外周动脉血管舒张。
完整处方资料附件：http://www.info.pmda.go.jp/go/pack/2149121F1021_1_02/

高血圧症治療剤「ザクラス®配合錠LD」および「ザクラス®配合錠HD」阿齐沙坦/苯磺酸氨氯地平复方片

Takeda Pharmaceutical Company Limited (“Takeda”) announced today that Zacras® combination tablets, a fixed-dose combination ("FDC") of azilsartan (generic name) and amlodipine besylate hydrochloride (generic name, "amlodipine"), and Azilva® tablets 10mg (generic name: azilsartan) are now available for treatment of hypertension in Japan.
Zacras is a tablet administrated orally once daily and has two dosage strengths, “Zacras® Combination Tablets LD” and “Zacras® Combination Tablets HD” which contain 20mg azilsartan/2.5mg amlodipine, and 20mg azilsartan / 5mg amlodipine respectively. Azilva tablets 10mg is the addition of a new dosage strength to already-marketed Azilva Tablets 20mg and 40mg.
Discovered by Takeda, azilsartan is a potent and lasting angiotensin II receptor blocker ("ARB") that lowers blood pressure by inhibiting the action of angiotensin II, a vasopressor hormone. Amlodipine is a calcium channel blocker ("CCB") having a hypotensive action by blocking inward calcium ion channels mainly in vascular smooth-muscle cells, resulting in peripheral arteriolar vasodilation. In a phase 3 clinical trial, the anti-hypertensive effect in diastolic blood pressure in the sitting position as the primary endpoint, of Zacras was statistically significant compared to monotherapy with either azilsartan or amlodipine.
The ARB-CCB combination is one of the recommended treatments regimens as a combination therapy for the hypertension in the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014), issued by the Japanese Society of Hypertension, from the standpoint of safety and efficacy. Simpler prescription using the FDC will improve adherence*, leading to improved blood pressure control.

References